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Accepted 29 May 2012Choriocarcinoma is a rare malignant spectrum of gesta-
tional trophoblastic disease (GTD) and may arise after
miscarriage, molar pregnancy, or term delivery. The inci-
dence of choriocarcinoma after miscarriage or term delivery
is estimated to be 1 in 50,000 pregnancies [1]. The ultra-
sound findings for choriocarcinoma can be normal, with an
elevated beta-human chorionic gonadotrophin (b-hCG) level.
Persistent disease is responsive to chemotherapy in more
than 90% of cases; based on World Health Organization
(WHO) risk scoring criteria, either single-agent or multi-
agent chemotherapy will be used [2]. However, 25% of those
with a high-risk WHO score and 5% with a low-risk WHO
score have an incomplete response to chemotherapy or
experience relapse following a period of remission [3].
Among these selected patients, surgical resection of local-
ized disease may be considered as an alternative approach.
In this paper, we present a case of focal recurrent chorio-
carcinoma successfully treated with laparoscopic surgical
resection without adjuvant chemotherapy.
A 32-year-old woman who had four previous pregnancies
presented to the emergency department during her early
gestational weeks with lower abdominal pain and a positive
urine pregnancy test. Physical examination revealed tender-
ness at the lower quadrant. Pelvic ultrasonographic examina-
tion showed a hyperechoic endometrial lining without
evidence of intrauterine pregnancy. A right solid hyperechoic
adnexal mass measuring 4 cm  3 cm was seen outside the* Corresponding author. Department of Obstetrics and Gynecology, Chang
Gung Memorial Hospital, Linkou Medical Center and Chang Gung University
College of Medicine, 5, Fu-Hsin Street, Kwei-Shan Tao-Yuan 333, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2013.04.027uterine cavity, along with fluid at the cul-de-sac. No fetal
activity was detected and findings were consistent with an
ectopic pregnancy. The b-hCG level was elevated at
7400 m IU/L. The patient underwent emergency laparoscopic
right salphingectomy and endometrial curettage. The intra-
operative finding was right tubal gestational tissue with
hemoperitoneum of 800 mL.
The histology of endometrial curettage and adnexa mass
were complete hydatidiform mole of the uterus and hemor-
rhagic trophoblastic cell of the right fallopian tube, respec-
tively. Postoperative follow-up revealed persistently elevated
levels of b-hCG (17,094 m IU/L). A diagnosis of GTD was
made. According to WHO scoring criteria, the patient was in
the low-risk group and received six cycles of single-agent
methotrexate (50 mg/m2).
Despite administration of single-agent chemotherapy, the
patient’s b-hCG levels remained high; therefore, a second-line
multiagent chemotherapy regimen, EMACO (etoposide
100 mg/m2, methotrexate 300 mg/m2, actinomycin 0.5 mg,
cyclophosphamide, and vincristine 1 mg/m2), was started. Her
b-hCG levels returned to a normal level after completion of
the second-line chemotherapy. The patient remained in
remission for 7 months.
However, after the period of remission, an incremental in-
crease of b-hCG level was noted. The patient was counseled
regarding the need for multiagent chemotherapy but she
refused this treatment. Computed tomography (CT) and
transvaginal ultrasonography were normal, fludeoxyglucose-
positron emission tomography (FDG-PET) scan showed a
focal F18 FDG uptake lesion in the right lower pelvic area
with maximum standardized uptake value of 4.7 (Fig. 1). CTcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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change. The patient was counseled regarding treatment op-
tions and she decided on the surgical resection of the focal
lesion via a laparoscopic approach. A diagnostic laparoscopy
revealed a focal right tumor at the anterior pelvic peritoneal
wall with a normal uterus. The focal pelvic tumor was excised
and histology confirmed recurrent choriocarcinoma (Figs. 2
and 3). Hysterectomy was not performed because a PET
scan showed negative biochemical intrauterine findings and
supported the intraoperative findings of a normal uterus. The
patient’s b-hCG level dramatically decreased from 364 m IU/L
to a normal level (<2 m IU/L) and her clinical condition
remained good after surgical resection of the focal tumor
without any evidence of port-site metastasis. There was no
evidence of recurrence 30 months after the treatment was
completed (Fig. 4).
Gestational trophoblastic neoplasm (GTN) is a rare ma-
lignancy that consists of a spectrum of interrelated tumors that
can be cured even in the presence of widespread metastases.
The spectrum of GTN includes invasive mole, choriocarci-
noma, placenta site trophoblastic tumor (PSTT), and epithe-
lioid trophoblastic tumor (ETT), which have several
propensities of invasion [4]. Hydatidiform moles, which act asFig. 1. Fludeoxyglucose-positron emission tomography computed tomography (FD
right lower pelvic area with evidence of suspicious recurrent choriocarcinoma.benign lesions, are mostly regarded as a precancerous lesion
because 16% of complete moles and 0.5% of partial moles can
be transformed into a malignant form of gestational tropho-
blastic neoplasm [5]. The incidence of GTD varies
geographically. The incidence of complete hydatidiform mole
is approximately 0.5e1 in 1000 pregnancies and partial
hydatidiform mole is three in 1000 pregnancies in Europe and
is highest in southeast Asia (up to 8 in 1000 pregnancies in
Thailand) [6,7]. Genetic, social, economic, and environmental
factors may play a role in these differences in geographical
incidence.
After evacuation of a complete mole, locally invasive GTN
occurs in 15% of patients and metastasis of GTN develops in
5% of patients [8]. In our patient, persistent elevation of serum
b-hCG levels after evacuation of a complete mole was the
clinical evidence for a diagnosis of choriocarcinoma.
Choriocarcinoma is often characterized by an early vascular
invasion with widespread blood-borne dissemination. The
most common sites of choriocarcinoma metastases are the
lung (80%), the vagina (30%), the pelvis (20%), the liver
(10%), and the brain (10%) [4,9]. Patients in whom GTN has
been diagnosed should undergo a thorough pretreatment
assessment to determine the extent of the disease. The WHOG PET CT) scan shows suspicious uptake and an F18 FDG avid lesion in the
Fig. 2. Laparoscopic view of a focal anterior intraperitoneal tumor lesion.
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risk and high-risk groups.
GTN is a chemosensitive tumor with a cure rate that is
steadily increasing and may exceed 90% [2]. Patients in the
low-risk group required single-agent methotrexate, whereas
those in the high-risk group should receive multiagent
chemotherapy because tumor resistance to single-agent ther-
apy is likely to develop. The most common regimen used as a
first-line multiagent chemotherapy is the EMACO regimen; it
was highly effective and well tolerated, with a 91% response
rate and 5-year survival rate of 75e90% [10]. Other regimens
that can be used as second-line treatment in those patients who
experience resistance to primary chemotherapy are CHA-
MOCA (methotrexate, dactinomycin, cyclophosphamide,
doxorubicin, melphalan, hydroxycarbamide, and vincristine),Fig. 3. Peritoneal tumor resection showing features of choriocarcinoma.
Hemorrhagic nodules adhered to the peritoneal fibroadipose tissue. A few
viable aggregates of syncytiotrophoblasts were seen in the blood clots (he-
matoxylin and eosin, 100).MAC (methotrexate, dactinomycin, cyclophosphamide), PVB
(cisplatin, vinblastine, bleomycin), and BEP (bleomycin, eto-
poside, and cisplatin) with a response rate of 71%, 95%, 62%,
and 74%, respectively [8,10,11].
Despite the success of chemotherapy in inducing a com-
plete response in GTN, approximately 5% of those in the low-
risk group and 25% of the high-risk group will have an
incomplete response to single-agent or multiagent chemo-
therapy or will relapse after a period of remission [3]. Our
patient relapsed with an isolated focal tumor after a short
remission.
In patients with drug resistance disease in whom the active
site of the tumor can be circumscribed to allow curative sur-
gical resection, an accurate localization of the lesion is crucial
for a successful remission. Various imaging studies are able to
identify a viable, active lesion in recurrent GTN. Sironi et al,
in their series of studies on recurrent GTN, reported FDG-PET
is superior in detecting lesions that are otherwise missed or
misinterpreted by conventional CT [12]. PET provides func-
tional information that is useful in differentiating viable
neoplastic tissue and necrotic lesion. The exact location of a
metastatic lesion is crucial because surgical resection may be
an important aspect of additional treatment. In our patients,
surgical resection of the tumor guided by PET scan has proved
to be successful in inducing remission.
Although the emergence of effective chemotherapy less-
ened the importance of surgical intervention in patients with
malignant GTN, in certain situations surgical resection is still
a viable option in the management of recurrent GTN. This
tumor tends to bleed profusely because of the great vascularity
of the trophoblastic tumor. Therefore, the surgeon should
proceed with caution during resection of local metastases. In
cases such as PSTT or ETT, hysterectomy plays an important
role as primary intervention because of the risk of uterine
perforation, which can lead to massive hemoperitoneum and
disseminated intraperitoneal disease, or severe vaginal
bleeding.
In our patients, laparoscopy is more beneficial compared
with laparatomy. In addition to shorter hospitalization, less
pain, earlier recovery, less morbidity, and better quality of life,
the laparoscopic approach provides a complete intraperitoneal
inspection and magnified visualization of any intraperitoneal
lesion missed by imaging. We are fully aware that the risk of
port-site metastasis is between 0e1.2% in laparoscopic
oncology cases. The exact etiology of port metastases is un-
known, but multiple factors have been implicated, such as
direct wound implantation, contamination of the instrument,
excessive manipulation of the tumor, and local and systemic
effects of pneumoperitoneum [13]. Our patients did not have
port-site metastasis and remained in remission after laparo-
scopic resection.
In summary, the options for management of recurrent
choriocarcinoma depend on various factors. With a focal
lesion, surgical resection should be considered to encourage
remission and avoid the need for adjuvant chemotherapy.
However, it is important to monitor levels of b-hCG so that
further recurrence can be detected.
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Fig. 4. A logarithm graphical representation of beta-human chorionic gonadotropin (b-hCG) levels. The x axis represents the date of b-hCG level taken throughout
surveillance and during treatment. The y axis represents the serum concentration of serial b-hCG.
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